Quantcast

Successful treatment of aciclovir and foscarnet resistant Herpes simplex virus lesions with topical imiquimod in patients infected with human immunodeficiency virus type 1.

Research paper by Anne-Sophie AS Lascaux, Eric E Caumes, Claire C Deback, Giovanna G Melica, Dominique D Challine, Henri H Agut, Yves Y Lévy

Indexed on: 16 Dec '11Published on: 16 Dec '11Published in: Journal of Medical Virology



Abstract

Aciclovir (ACV)-resistant Herpes simplex virus type-2 (HSV-2) infections are observed commonly in patients also infected with HIV-1. The use of foscarnet (FOS) in these patients may also lead to resistance. This situation can become a difficult therapeutic challenge. Four cases of patients infected with HIV and with mucocutaneous HSV-2 resistant to ACV and FOS are reported. These patients were treated successfully with topical 5% imiquimod. Imiquimod treatment also appeared to delay the time to recurrence of HSV lesions.

More like this: